Trial Profile

An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients With Open Angle Glaucoma or Ocular Hypertension

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 15 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bimatoprost (Primary)
Indications Ocular hypertension; Open-angle glaucoma
Focus Adverse reactions; Therapeutic Use
Acronyms MAIA
Sponsors AbbVie; AbbVie Germany; Allergan

Most Recent Events

10 Nov 2023 Planned End Date changed from 13 Jun 2025 to 7 Aug 2026.
10 Nov 2023 Planned primary completion date changed from 13 Jun 2025 to 7 Aug 2026.
08 Jul 2023 This trial has been completed in Belgium.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com